Page 9 - 2d News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from 2d. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In 2d Today - Breaking & Trending Today

Arm Fat Raises CVD Risk in People With Type 2 Diabetes

In people with type 2 diabetes, cardiovascular disease risk was higher with extra fat on the arms or trunk and lower with extra fat on the legs. ....

United Kingdom , Zixin Qiu , Tongji Medical College , School Of Public Health , Huazhong University Of Science , United Kingdom Biobank , Public Health , Huazhong University , Clinical Endocrinology , White United Kingdom , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Ype 2 Dm , Body Mass Index , Cv Risk , Cardiovascular Risk , V Risk Factors , Cardiovascular Risk Factors , Cardiovascular Risk Management , Cardiovascular Disease , Vd Cardiovascular Disease , Uk Site Content United Kingdom , United Kingdom , Ndocrine System ,

Can Short Cycles of a Fasting-Like Diet Reduce Disease Risk?

Monthly cycles of a 5-day FMD (plant-based, low-calorie, and low-protein) followed by a normal diet appeared to improve markers of prediabetes and immune system aging. ....

United States , New Haven , Morgane Levine , Los Angeles , Sebastian Brandhorst , Yale School Of Medicine , Department Of Pathology , University Of Southern California , National Health , Nature Communications , Leonard Davis School Of Gerontology , Nutrition Examination , Leonard Davis School , Southern California , Yale School , Metabolic Syndrome , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Healthcare Technology , Medical Technology , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Ype 2 Dm ,

Semaglutide Beneficial in HFpEF Patients With Diabetes

In patients with HFpEF and obesity, symptom reduction and weight loss provided by semaglutide extends to those with diabetes, suggest new data from the STEP-HFpEF DM trial. ....

United States , Mikhailn Kosiborod , Bethl Abramson , Clinical Research , American College Of Cardiology , University Of Toronto , Luke Health System , Health System , Kansas City , Study Entry , Featured Clinical Research , American College , New England Journal , Are Significantly Lower , Heart Failure , Weight Loss , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Ype 2 Dm , Weight Management , Quality Of Life , Ealth Related Quality Of Life , Cardiovascular Imaging , Ardiac Imaging , V Imaging ,

Empagliflozin Fails to Reduce Events After Acute MI

Empagliflozin did not significantly reduce overall HF hospitalization or all-cause death in high-risk patients in EMPACT-MI but did reduce first and total hospitalizations. ....

New York , United States , James Januzzi , Deepak Bhatt , Valentin Fuster , Carine Hamo , Michelle Albert , Javed Butler , Baylor Scott White Research Institute , American College Of Cardiology , Grossman School Of Medicine , Leonh Charney Division Of Cardiology , Department Of Medicine , American College , Scientific Sessions , New England Journal , Baylor Scott , White Research Institute , Mount Sinai Heart , Icahn School , Mount Sinai Health System , New York City , Lancet Diabetes , Myocardial Infarction , Heart Failure , Sglt2 Inhibitors ,

SGLT2 Inhibitors Safe for HF in Congenital Heart Disease

SGLT2 inhibitors not only were safe in adult patients with congenital heart disease who develop heart failure but also were associated with reduced hospitalizations. ....

United States , University Medical Center , Anastasiad Egorova , Lukej Burchill , Journal Of The American College Cardiology , European Society Of Cardiology , Department Of Cardiovascular Medicine , Leiden University Medical Center , American College , European Society , Cardiovascular Medicine , Mayo Clinic , Heart Failure , Sglt2 Inhibitors , Odium Glucose Transporter 2 Inhibitors , Odium Glucose Co Transporter 2 Inhibitors , Sodium Glucose Cotransporter 2 Inhibitors , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Ype 2 Dm , Congenital Heart Disease , Adverse Effects , Side Effects , Patient Safety , Skin And Soft Tissue Infection ,